Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Capivasertib · Truqap, TRUQAP

Small molecule · Inhibitor of AKT1, AKT2 and AKT3 · developed by Astrazeneca

Approved FDA, Nov 2023
AZN Developer
3 Registered trials

What is Capivasertib?

Capivasertib is an orally available pyrrolopyrimidine inhibitor of all three AKT isoforms (AKT1, AKT2 and AKT3), blocking phosphorylation of downstream AKT substrates in the PI3K/AKT pathway. It is studied in breast cancer, including triple-negative and PIK3CA-mutated disease, and in prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Truqap, TRUQAP, AZD-5363
Drug type
Small molecule
Targets
AKT1, AKT2, AKT3, PTEN (biomarker), PIK3CA (biomarker)
Mechanism
Inhibitor of AKT1, AKT2 and AKT3
Pathways
PI3K/AKT/mTOR signaling, phosphorylation of AKT substrates, apoptosis, glucose and fatty acid metabolism
Therapy area
Oncology
Developer
Astrazeneca (AZN)
Also in trials of
CRDF, RLAY
FDA status
Approved as Truqap (November 16, 2023), NDA218197 · FDA label
UNII
WFR23M21IE

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 12, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06982521 Phase 3 PIK3CA Mutation Recruiting RLAY
NCT03742102 Phase 1/2 Triple Negative Breast Neoplasms Active not recruiting AZN
NCT01992952 Phase 1/2 Estrogen Receptor Positive Breast Cancer Active not recruiting CRDF

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Breast CancerBreast CancerEstrogen Receptor Positive Breast CancerHER2- Negative Breast CancerHormone Receptor Positive TumorMetastatic Breast CancerPIK3CA MutationTriple Negative Breast Neoplasms

Other drugs acting on AKT1 / AKT2 / AKT3

More from Astrazeneca

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Capivasertib

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.